B型钠尿肽在心力衰竭诊断治疗中的应用

Clinical application of B type natriuretic peptide in the diagnosis and treatment of heart failure

目的探讨B型钠尿肽(BNP)在心力衰竭临床诊断与治疗中应用价值。方法选取2013年1月-2014年6月收治的不同程度充血性心力衰竭患者198例作为CHF组,同时选取其他科室中心、肺功能正常,无其他慢性疾病的非心力衰竭患者202名作为健康对照组,测定受试者BNP浓度水平与左室射血分数(LVEF)并作比较。结果CHF组血浆BNP浓度(328.4±148.7)pg/ml明显高于健康对照组的(18.3±6.9)pg/ml,差异有统计学意义(P<0.05)。CHF组血浆BNP浓度水平NYHA分级各级间比较差异均有统计学意义(P<0.05)。结论 BNP在心力衰竭疾病诊断与治疗中是十分关键的观测要素,可作为疾病预测参考因子,能够对患者心力衰竭程度及后期发展情况做出一定的判断。

Objective To explore the application value of B type natriuretic peptide（BNP） in the clinical diagnosis and treatment process of heart failure. Methods From January 2013 to June 2014,198 patients with heart failure were selected as the CHF group, and 202 patients from other departments without heart failure were as the healthy control group. The BNP concentration and Left ventricular ejection fraction （LVEF） of 2 groups were compared. Results The BNP concentration （328.4 ± 148.7pg/ml ）of the CHF group was higher compared with healthy patients（ 18.3 ± 6.9pg/ml） , and the difference was statistical significance （P 〈 0.05 ）. In CHF group, the NYHA classification of the plasma BNP levels was difference, and the difference was statistical significance （P 〈 0. 05 ）. Conclusion In the diagnosis and treatment process of heart failure, BNP is a crucial observation elements,which can be used as a disease prediction reference factor, and help doctor to make a certain judgments on the degree of heart failure and later development of disease.